AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26994987 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabies-Conventional
Number of subjects: 661
Study 26994987 — intervention group
Group type: COMPARATOR
Intervention: JE-Conventional
Number of subjects: 661
Study 25265572 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood
Number of subjects: 32
Study 25265572 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood (control)
Number of subjects: 32
Study 22893265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 353
Study 22893265 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 353
Study 20581041 — intervention group
Group type: EXPERIMENTAL
Intervention: 1SET
Number of subjects: 8
Study 20581041 — intervention group
Group type: EXPERIMENTAL
Intervention: 3SET
Number of subjects: 8
Study 20581041 — intervention group
Group type: COMPARATOR
Intervention: 1SET and 3SET
Number of subjects: 8
Study 18076234 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear periodization (n = 9)
Number of subjects: 28
Study 18076234 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily undulating periodization (n = 10)
Number of subjects: 28
Study 18076234 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly undulating periodization (n = 9)
Number of subjects: 28
Study 16207768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 0
Study 16207768 — intervention group
Group type: COMPARATOR
Intervention: Happy mood
Number of subjects: 0
Study 12366698 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL) 25 mg (Nemexin)
Number of subjects: 11
Study 12366698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 9665535 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks immobilization
Number of subjects: 100
Study 9665535 — intervention group
Group type: COMPARATOR
Intervention: 5 weeks immobilization
Number of subjects: 100
Study 7641913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GnRH agonist (GnRH-a) and hMG therapy
Number of subjects: 70
Study 7641913 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) and hMG therapy
Number of subjects: 70
Study 2767075 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-adapted AVD pacing (AVD reduced by 20 ms every 10 beats min-1 from 220 ms at 90 beats min-1 to 100 ms at 150 beats min-1)
Number of subjects: 10
Study 2767075 — intervention group
Group type: COMPARATOR
Intervention: Fixed 200 ms AVD
Number of subjects: 10
Study 2767075 — intervention group
Group type: COMPARATOR
Intervention: Fixed 150 ms AVD
Number of subjects: 10
Study 791468 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 791468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 791468 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 12
Study 791468 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (long-term therapy)
Number of subjects: 12
Study 31247674 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 17
Study 31247674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 28329366 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% biofeedback
Number of subjects: 48
Study 28329366 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary feedback
Number of subjects: 48
Study 28329366 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% biofeedback
Number of subjects: 48
Study 28329366 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 48
Study 26359441 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 261
Study 26359441 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 261
Study 23470183 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Action program
Number of subjects: 1784
Study 21272190 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/day MK-0916
Number of subjects: 120
Study 21272190 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0916 (0.5, 2, or 6 mg/day)
Number of subjects: 120
Study 21272190 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0916
Number of subjects: 120
Study 21272190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19812809 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 74
Study 19812809 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 74
Study 18001406 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg daily (EAC group, n = 209)
Number of subjects: 420
Study 18001406 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.i.d. (RAC group, n = 211)
Number of subjects: 420
Study 18001406 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg daily (EAC group)
Number of subjects: 420
Study 18001406 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg b.i.d. (RAC group)
Number of subjects: 420
Study 15145166 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy (CHT-RT) alone (Group 1)
Number of subjects: 24
Study 15145166 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant TPF followed by CHT-RT (Groups 2 and 3)
Number of subjects: 24
Study 15145166 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant TPF (Groups 2 and 3)
Number of subjects: 24
Study 15145166 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant TPF followed by two cycles of PF during RT (Group 3)
Number of subjects: 24
Study 11443492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐fat, high‐simple carbohydrate diet (SCHO)
Number of subjects: 24
Study 11443492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐fat, high‐complex carbohydrate diet (CCHO)
Number of subjects: 24
Study 11443492 — intervention group
Group type: COMPARATOR
Intervention: Habitual control diet (CD)
Number of subjects: 24
Study 9219866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg p.o.)
Number of subjects: 0
Study 9219866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (30 mg p.o.)
Number of subjects: 0
Study 9219866 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol (20 mg p.o.)
Number of subjects: 0
Study 9219866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8396085 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily for three days
Number of subjects: 380
Study 8396085 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg bid for ten days
Number of subjects: 380
Study 8396085 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin for sinusitis
Number of subjects: 380
Study 8396085 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin for sinusitis
Number of subjects: 380
Study 8396085 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin for pharyngitis or tonsillitis
Number of subjects: 380
Study 8396085 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin for pharyngitis or tonsillitis
Number of subjects: 380
Study 8396085 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 380
Study 8396085 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 380
Study 3531845 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11
Study 3531845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31351791 — intervention group
Group type: EXPERIMENTAL
Intervention: Toshiba Aplio MX
Number of subjects: 196
Study 31351791 — intervention group
Group type: COMPARATOR
Intervention: GE Vivid E9
Number of subjects: 196
Study 31351791 — intervention group
Group type: COMPARATOR
Intervention: Philips EPIQ
Number of subjects: 196
Study 31351791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra- and interobserver repeatability
Number of subjects: 196
Study 29489037 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 160
Study 29489037 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 160
Study 26484794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of glimepiride and atorvastatin (once daily for 20 weeks)
Number of subjects: 427
Study 26484794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of glimepiride and atorvastatin
Number of subjects: 427
Study 26484794 — intervention group
Group type: COMPARATOR
Intervention: Co-administered glimepiride and atorvastatin (once daily for 20 weeks)
Number of subjects: 427
Study 26484794 — intervention group
Group type: COMPARATOR
Intervention: Co-administered glimepiride and atorvastatin
Number of subjects: 427
Study 24106325 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid‐Heat
Number of subjects: 25
Study 24106325 — intervention group
Group type: COMPARATOR
Intervention: Hygrobac
Number of subjects: 25
Study 24106325 — intervention group
Group type: COMPARATOR
Intervention: Hygrobac S
Number of subjects: 25
Study 22251913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation learning experience
Number of subjects: 28
Study 22251913 — intervention group
Group type: COMPARATOR
Intervention: Standard teaching methods (discussion, video, low-fidelity methods)
Number of subjects: 28
Study 20309682 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 12
Study 20309682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20309682 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (20 mg)
Number of subjects: 12
Study 17686442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and pemetrexed combination therapy; standard treatment based on phase III-study evidence; initiation of therapy as early as possible.
Number of subjects: 0
Study 17686442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour markers and genomic analysis for early diagnosis; still under investigation.
Number of subjects: 0
Study 17686442 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert panel confirmation of histological samples to exclude other tumours; no specific intervention details provided.
Number of subjects: 0
Study 17686442 — intervention group
Group type: EXPERIMENTAL
Intervention: IMIG staging system requiring surgical intervention; no specific intervention details provided.
Number of subjects: 0
Study 15831613 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MI heart failure or major LVSD management
Number of subjects: 1
Study 12741630 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir, didanosine, and stavudine
Number of subjects: 60
Study 10822318 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm ergometry (ARM) at 65% VO2 peak
Number of subjects: 9
Study 10822318 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg ergometry (LEG) at 70% VO2 Peak
Number of subjects: 9
Study 8865618 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique novel object amidst familiar distractors
Number of subjects: 0
Study 8865618 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar target in a display of intermediate set size
Number of subjects: 0
Study 1729021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous heparin administration (1000 U bolus followed by 500 U every 30 minutes)
Number of subjects: 286
Study 1729021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous heparin administration (1000 U or 1500 U initial bolus followed by continuous heparin infusion)
Number of subjects: 286
Study 1729021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous heparin administration (1000 U bolus before hip dislocation, and 500 U bolus before femoral canal preparation)
Number of subjects: 286
Study 1729021 — intervention group
Group type: COMPARATOR
Intervention: Control group (intraoperative saline)
Number of subjects: 286
Study 1729021 — intervention group
Group type: EXPERIMENTAL
Intervention: All heparin groups combined
Number of subjects: 286
Study 6488826 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen catheter (DLC)
Number of subjects: 27
Study 6488826 — intervention group
Group type: COMPARATOR
Intervention: Tracheal aspirates
Number of subjects: 27
Study 3729509 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule
Number of subjects: 25
Study 3729509 — intervention group
Group type: COMPARATOR
Intervention: Hard gelatin capsule
Number of subjects: 25
Study 3729509 — intervention group
Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 25
Study 31310299 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU diary filled in by clinicians and family members (n=355)
Number of subjects: 709
Study 31310299 — intervention group
Group type: COMPARATOR
Intervention: Usual ICU care without an ICU diary (n=354)
Number of subjects: 709
Study 31310299 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 709
Study 31310299 — intervention group
Group type: COMPARATOR
Intervention: Usual ICU care
Number of subjects: 709
Study 29138201 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron- and zinc-biofortified pearl millet (FeZn-PM)
Number of subjects: 200
Study 29138201 — intervention group
Group type: COMPARATOR
Intervention: Non-biofortified pearl millet
Number of subjects: 200
Study 25796021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (Group K)
Number of subjects: 90
Study 25796021 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (Group A)
Number of subjects: 90
Study 25796021 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90
Study 24262040 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (observation group)
Number of subjects: 100
Study 24262040 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant or antiplatelet medicine (control group)
Number of subjects: 100
Study 21396090 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal pessaries (100mg) for 6 days
Number of subjects: 98
Study 21396090 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no treatment)
Number of subjects: 98
Study 18677509 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 51
Study 18677509 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemostatic techniques
Number of subjects: 51
Study 16599352 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants
Number of subjects: 120
Study 16599352 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight participants
Number of subjects: 120
Study 16599352 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight participants
Number of subjects: 120
Study 16599352 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight and overweight participants
Number of subjects: 120
Study 12855212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral obesity intervention
Number of subjects: 665
Study 11060719 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (e.g., amprenavir, indinavir, nelfinavir, ritonavir, saquinavir)
Number of subjects: 0
Study 11060719 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparisons between various licensed protease inhibitors
Number of subjects: 0
Study 11060719 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparisons of protease inhibitors to other classes of potent antiretroviral drugs
Number of subjects: 0
Study 11060719 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigations with new protease inhibitors
Number of subjects: 0
Study 11060719 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigations of protease inhibitor‐related toxicities
Number of subjects: 0
Study 11060719 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempts at simplifying current dosing regimens
Number of subjects: 0
Study 8777207 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous intrapleural procedures (major and minor)
Number of subjects: 18
Study 8777207 — intervention group
Group type: EXPERIMENTAL
Intervention: Major previous intrapleural procedures
Number of subjects: 18
Study 8777207 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major previous intrapleural procedures
Number of subjects: 18
Study 8777207 — intervention group
Group type: COMPARATOR
Intervention: Controls (no previous intrapleural procedures)
Number of subjects: 18
Study 1390510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (E) treated infants
Number of subjects: 914
Study 1390510 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) treated infants
Number of subjects: 914
Study 2988769 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 119
Study 2988769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TPN)
Number of subjects: 119
Study 29966931 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 457
Study 29966931 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 457
Study 27215733 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based ACT (n = 82)
Number of subjects: 236
Study 27215733 — intervention group
Group type: COMPARATOR
Intervention: waiting list (n = 87)
Number of subjects: 236
Study 27215733 — intervention group
Group type: COMPARATOR
Intervention: web‐based Expressive Writing (EW; n = 67)
Number of subjects: 236
Study 24798205 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Education and Self Management for Ongoing and Newly Diagnosed Type 2 diabetes (DESMOND) course delivered by one trained lay educator and one professional educator
Number of subjects: 260
Study 24798205 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the standard format DESMOND course delivered by two trained healthcare professional educators
Number of subjects: 260
Study 22448846 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation
Number of subjects: 46
Study 22448846 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 46
Study 22448846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 20205074 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (5 or 10 mg BID)
Number of subjects: 1225
Study 20205074 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg QD)
Number of subjects: 1225
Study 18555147 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with local anesthetics combined with opioids (T(9)-T(10); group A)
Number of subjects: 40
Study 18555147 — intervention group
Group type: COMPARATOR
Intervention: IV analgesia with morphine (group B)
Number of subjects: 40
Study 18555147 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both groups)
Number of subjects: 40
Study 16020142 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly sessions of time‐limited theme‐based group psychotherapy for 6 months and 50 mg sildenafil citrate orally on demand
Number of subjects: 30
Study 16020142 — intervention group
Group type: COMPARATOR
Intervention: 50 mg sildenafil citrate orally on demand for 6 months only
Number of subjects: 30
Study 16020142 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly sessions of time‐limited theme‐based group psychotherapy for 6 months
Number of subjects: 30
Study 12830470 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid dialysate (Nutrineal; DAA group, n = 30)
Number of subjects: 60
Study 12830470 — intervention group
Group type: COMPARATOR
Intervention: Dextrose dialysate (Dianeal; DD group, n = 30)
Number of subjects: 60
Study 10426519 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal diencephalic damage
Number of subjects: 0
Study 10426519 — intervention group
Group type: EXPERIMENTAL
Intervention: Korsakoff patients
Number of subjects: 0
Study 10426519 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal lobe pathology
Number of subjects: 0
Study 10426519 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lobe pathology
Number of subjects: 0
Study 10426519 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal lobe and temporal lobe groups
Number of subjects: 0
Study 10426519 — intervention group
Group type: EXPERIMENTAL
Intervention: Right temporal and frontal lobe regions
Number of subjects: 0
Study 10426519 — intervention group
Group type: EXPERIMENTAL
Intervention: Left temporal region
Number of subjects: 0
Study 7595137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g elemental calcium administered twice daily for 16 weeks
Number of subjects: 32
Study 7595137 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily for 16 weeks
Number of subjects: 32
Study 2212566 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4-MP)
Number of subjects: 15
Study 2212566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 382153 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone suppositories (30 mg)
Number of subjects: 60
Study 382153 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide suppositories (10 mg)
Number of subjects: 60
Study 382153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31295335 — intervention group
Group type: EXPERIMENTAL
Intervention: Group antenatal and postnatal care (ANC/PNC)
Number of subjects: 0
Study 31295335 — intervention group
Group type: COMPARATOR
Intervention: Traditional individual model of ANC/PNC
Number of subjects: 0
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled BP (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg)
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled BP in Bangladesh
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled BP in Pakistan
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled BP in Sri Lanka
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower wealth index
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vs. married
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher log urine albumin‐to‐creatinine ratio
Number of subjects: 1718